Improve DNA Synthesis Screening for Sequences of Concern
This guide walks you through strengthening your DNA synthesis screening workflow to better identify sequences of concern before they are manufactured. You’ll learn how to layer automated screening tools, refine your hit review process, and keep your screening aligned with current biosecurity best practices. No specialized software is required to start, but you’ll need access to your current screening logs and a basic understanding of your order pipeline.
What You’ll Need
- Access to your current DNA synthesis order database or spreadsheet
- Basic familiarity with BLAST or similar sequence alignment tools
- A list of regulated or concern sequences (e.g., from the International Gene Synthesis Consortium or national guidelines)
- Text editor or spreadsheet software for documenting changes
Step-by-Step
- Audit your current screening process. Map out how orders are currently reviewed: Which sequences get flagged? What thresholds are used? How are hits confirmed? Identify gaps—for example, if you only screen for exact matches, you’ll miss sequences with minor variations.
- Define what constitutes a “sequence of concern� for your organization. This goes beyond just regulated pathogens. Consider including toxin genes, virulence factors, or sequences with dual-use potential. Write a clear definition that your screening team can apply consistently.
- Implement tiered screening. Start with a fast, broad screen (e.g., k-mer based) to catch obvious hits, then follow up with a more sensitive alignment (like BLAST) for borderline cases. This balances speed with accuracy.
- Use a curated database of concern sequences. Maintain a local, regularly updated database of sequences that you compare against. Include not just the exact sequences, but also known variants and functional domains.
- Screen both the full sequence and fragments. A common gap is screening only the full-length gene. Break the order into overlapping fragments (e.g., 100-200 bp) and screen each fragment separately. This catches sequences that are split across multiple synthesis constructs.
- Incorporate functional screening. If the sequence encodes a protein, check if the translated protein matches a known toxin or virulence factor, even if the nucleotide sequence differs due to codon optimization.
- Set clear thresholds and scoring. Define what similarity score triggers a manual review (e.g., BLAST E-value < 1e-5 or >80% identity over 100 bp). Document these thresholds so the process is reproducible.
- Establish a manual review workflow. When a sequence is flagged, have a trained reviewer examine it. The reviewer should consider the intended use, the customer’s history, and any additional context. Create a decision tree for common scenarios.
- Document every decision. Log all flagged sequences, the screening results, the reviewer’s decision, and the rationale. This is crucial for audits and for improving your screening over time.
- Regularly update your screening database and thresholds. New threats emerge, and your screening should evolve. Set a quarterly review to add new sequences and adjust thresholds based on false positives/negatives you’ve seen.
- Train your team. Ensure everyone involved understands the screening process, the definition of concern, and how to use the tools. Regular training reduces human error and improves consistency.
- Test your screening with mock orders. Periodically submit test sequences (including known concern sequences and benign controls) to verify that your screening catches them and doesn’t over-flag benign orders.
Common Mistakes
- Only screening exact matches. This misses sequences with silent mutations or codon optimization.
- Ignoring short fragments. Pathogen genes can be split across multiple order constructs; screening only full-length sequences misses these.
- Not updating the database. Using an outdated list of concern sequences can lead to missing newly identified threats.
- Over-reliance on automated flags. Automated screening is a first pass, not a final answer. Skipping manual review for borderline hits can lead to false negatives.
- Inconsistent thresholds. If different reviewers use different criteria, you’ll get inconsistent results and potential gaps.
Tips
- Use a scoring system that combines similarity, length of match, and functional annotation to rank flags by severity.
- Consider using a cloud-based screening service that updates its database automatically, but ensure you understand their methodology.
- When in doubt, escalate to a senior reviewer or biosecurity officer.
- Keep a “gray list� of sequences that are not clearly concerning but warrant extra scrutiny based on customer context.
- Collaborate with other synthesis providers to share threat intelligence (while respecting confidentiality).
Troubleshooting
- Too many false positives: If your screening flags too many benign orders, adjust your thresholds (e.g., increase the E-value cutoff or require a longer match length). Also, check if your database includes sequences that are too broad (e.g., including housekeeping genes).
- Missed sequences of concern: If you discover a missed hit, review your screening logs to see where it slipped through. Was it a fragment issue? Did the database lack the sequence? Update your process accordingly.
- Screening too slow: If your screening is a bottleneck, optimize by using a faster initial filter (like k-mer) before running BLAST. Also, consider parallelizing the screening across multiple servers.
- Inconsistent results between reviewers: Standardize your review process with a detailed checklist and decision tree. Provide examples of edge cases and how to handle them.
- Database corruption or errors: Regularly back up your database and validate it with known sequences to ensure it’s working correctly.
Frequently Asked Questions
Q: What is the minimum similarity score that should trigger a review?
A: There’s no universal number, but a common practice is to flag any BLAST hit with an E-value below 1e-5 or >80% identity over a 100 bp window. Adjust based on your risk tolerance and the length of the sequence.
Q: Should I screen against the entire GenBank database?
A: No, that’s too broad and will produce many false positives. Instead, curate a focused database of known threat sequences, such as those from the International Gene Synthesis Consortium’s list.
Q: How often should I update my screening database?
A: At least quarterly, but more frequently if new threats are identified. Subscribe to biosecurity alerts from relevant agencies.
Q: Can I screen for sequences that are codon-optimized?
A: Yes, by translating the nucleotide sequence to protein and screening the protein sequence. This catches functional homologs even if the DNA sequence is different.
Q: What if a customer’s order is flagged but they provide a legitimate use case?
A: That’s where manual review comes in. If the use case is legitimate (e.g., vaccine research), you can approve it, but document the rationale. If in doubt, escalate to a biosecurity expert.
Q: Do I need to screen every order, even short oligos?
A: Yes, even short oligos can be problematic if they are part of a larger assembly. Screen all orders, but you can adjust the threshold for shorter sequences (e.g., require a higher identity).
Related
Method: the standard formula for this calculation, rounded as each result states. See how the calculators work or report an error.